TY - CHAP
T1 - Combination Therapies Targeting the PI3K/AKT/mTOR Pathways
AU - Naing, Aung
AU - Mills, Gordon B.
AU - Meric-Bernstam, Funda
N1 - Publisher Copyright:
© Springer Science+Business Media New York 2016.
PY - 2016
Y1 - 2016
N2 - The phosphoinositide 3-kinase (PI3K) pathway was first described by Lewis C. Cantley’s group in 1998 (Fruman et al. in Annu Rev Biochem 67:481–507, 1998, [1]; Cantley in Science 296(5573):1655–1657, 2002, [2]). Upon activation, PI3K signaling can act on diverse downstream substrates (Cantley in Science 296(5573):1655–1657, 2002, [2]; Laplante and Sabatini in Cell 149(2):274–293, 2012, [3]). The PI3K pathway that includes AKT and mTOR contributes to many events that are critical for normal and pathophysiological cell metabolism, regulation of gene expression, cytoskeletal rearrangement, and cell survival.
AB - The phosphoinositide 3-kinase (PI3K) pathway was first described by Lewis C. Cantley’s group in 1998 (Fruman et al. in Annu Rev Biochem 67:481–507, 1998, [1]; Cantley in Science 296(5573):1655–1657, 2002, [2]). Upon activation, PI3K signaling can act on diverse downstream substrates (Cantley in Science 296(5573):1655–1657, 2002, [2]; Laplante and Sabatini in Cell 149(2):274–293, 2012, [3]). The PI3K pathway that includes AKT and mTOR contributes to many events that are critical for normal and pathophysiological cell metabolism, regulation of gene expression, cytoskeletal rearrangement, and cell survival.
KW - Drug resistance
KW - Dual inhibitors
KW - Feedback loops
KW - Predictors of response
KW - Regulators of PI3K/AKT/mTOR pathway
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=85144718238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144718238&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-34211-5_6
DO - 10.1007/978-3-319-34211-5_6
M3 - Chapter
AN - SCOPUS:85144718238
T3 - Cancer Drug Discovery and Development
SP - 151
EP - 180
BT - Cancer Drug Discovery and Development
PB - Humana Press Inc.
ER -